Sio Gene Therapies Inc (SIOX)

NASDAQ
1.410
-0.080(-5.37%)
After Hours
1.380
-0.030(-2.128%)
- Real-time Data
  • Volume:
    634,540
  • Bid/Ask:
    1.370/1.430
  • Day's Range:
    1.380 - 1.480

SIOX Overview

Prev. Close
1.49
Day's Range
1.38-1.48
Revenue
-
Open
1.45
52 wk Range
1.38-4.15
EPS
-0.7
Volume
634,540
Market Cap
103.62M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,252,760
P/E Ratio
-
Beta
1.57
1-Year Change
-46.39%
Shares Outstanding
73,488,721
Next Earnings Date
Feb 08, 2022
What is your sentiment on Sio Gene Therapies Inc?
or
Market is currently closed. Voting is open during market hours.

Sio Gene Therapies Inc Company Profile

Employees
42

Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellStrong SellStrong Sell
Technical IndicatorsNeutralBuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell
  • time is due I see you in the double digits 😎
    0
    • What floats and looks like a snickers bar?
      0
      • Whaatt
        0
        • Sky is the limit
          0
          • NEWS. Shelf offering .They will add most likely 10 mil. new shares. They say in new filing this will be on open market. Caution
            0
            • Shares Outstanding 48,467,922 Volume today: 45,770,746 Somebody made millions selling  from $3.75 to $4.15
              0
              • all green tomorrow 🔥
                0
                • See you at @ $2.5 this week.
                  0
              • Wat happened this was blowing up
                0
                • Fake and misleading news. Positive  is not "positive" Sold all at $3.6. All insiders  and  institutional holders sold above $3.75. Scam
                  0
              • Garbage
                0
                • this should hit $4.5 today
                  1
                  • Why is this up??
                    0
                    • Positive data on an important clinical study
                      0
                    • Yeah read it aftermarket but still sold my +-$8000 worth of shares before market close, bummer
                      0
                  • Anyone watching?
                    0
                    • New chief commercial officer appointed, things are getting really interesting
                      0
                      • Crazy move ahead, stay tuned
                        0
                        • Something is moving on under the radar
                          0
                          • What’s going on with this one?
                            0
                            • Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy. GlobeNewswire•March 11, 2019. Generally well-tolerated with no serious adverse events in a 30-month-old patient with advanced infantile Tay-Sachs disease. Stable clinical condition from baseline to month 3 without deterioration on neurological exam. Increase in CSF β-Hexosaminidase A enzyme activity from baseline to month 3, surpassing the 0.5% threshold expected for a clinically important effect. Axovant to present at the Cowen and Company 39th Annual Health Care Conference on March 11th at 12:00 PM (Eastern Time). NEW YORK and BASEL, Switzerland, March 11, 2019 (GLOBE NEWSWIRE) -- Axovant (AXGT), a clinical-stage company developing innovative gene therapies,
                              0
                              • Axovant Reports Positive Interim Results From First Cohort Of SUNRISE *****Phase 2 Trial Of AXO-Lenti *****Gene Therapy In Parkinson’s Disease
                                0
                                • got it 1.23 sold 1.30 full moon. hahaha
                                  0
                                  • damn - cant wait to sell
                                    0
                                    • Good buy? Or no?
                                      1
                                      • Going to the
                                        0
                                        • Got it at $1.76 oh yeah baby going to the moon
                                          0
                                          • Looks like you know what you're doing. can you give me advice?
                                            0
                                        • short from 11.07 / 11.77
                                          0
                                          • what a nice short.....I will be ready
                                            0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.